Publication date: 21/09/2017
Mithra (Euronext Brussels: MITRA), a company specialized in women’s health, today announces its financial results for the six-month period ending 30 June 2017, prepared in accordance with IFRS. The full interim report is available on the website in the Investors section (investors.mithra.com).
Operational Highlights (including post-period end)
François Fornieri, CEO of Mithra, commented:
"I am pleased to report significant progress during the first six months of the year, both in terms of advancing our pipeline programs and delivering on Mithra’s corporate objectives. Our advanced E4-based programs for Estelle® in contraception and Donesta® in menopause are progressing according to schedule, as are the Complex Therapeutics programs Myring™, Zoreline® and Tibelia®. Business development activities continued to accelerate, including partnerships with Fuji Pharma for Donesta® and Mayne Pharma for Myring™. These collaborations are an endorsement of the commercial potential of our products and further highlight Mithra’s growing reputation in the increasingly attractive field of women’s health.
The Company also strengthened its financial position thanks to an oversubscribed private placement of EUR 26.1 million. The fundraising was supported by existing shareholders as well as new, specialized life sciences investors, demonstrating investor confidence in Mithra’s strategy to become a fully-fledged biopharmaceutical company. The additional funding will be used to advance our lead clinical programs while also allowing the Company to pursue further business development opportunities to realize the full commercial potential of our pipeline programs. With a strengthened financial position, continued progress on all our key programs and accelerating partnering discussions, we look forward to the rest of 2017 with confidence.”
Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in Women’s Health, with a particular focus on fertility, contraception and menopause. Mithra’s goal is to develop new and improved products that meet women’s needs for better safety and convenience. Its two lead development candidates – a fifth generation oral contraceptive Estelle® and next-generation hormone therapy Donesta® - are built on Mithra’s unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO. Mithra was founded in 1999 as a spin-off from the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart. Mithra is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com.